Out Of Stealth, Artax Hopes To Pioneer Nck Targeting In Autoimmune Disease
$10 million Series B will enable lead candidate AX-024 to advance into Phase IIa in undetermined autoimmune indications.
$10 million Series B will enable lead candidate AX-024 to advance into Phase IIa in undetermined autoimmune indications.